US 12,257,241 B2
Rifabutin treatment methods, uses, and compositions
Glenn E. Dale, Basel (CH); Sergio Lociuro, Basel (CH); Christian Kemmer, Riehen (CH); Vincent Trebosc, Rixheim (FR); and Marc Gitzinger, Laufenburg (CH)
Assigned to BIOVERSYS AG, Basel (CH)
Filed by BIOVERSYS AG, Basel (CH)
Filed on Oct. 20, 2023, as Appl. No. 18/491,243.
Application 18/491,243 is a continuation of application No. 17/833,326, filed on Jun. 6, 2022, granted, now 11,833,139.
Application 17/833,326 is a continuation of application No. 16/983,689, filed on Aug. 3, 2020, granted, now 11,351,158, issued on Jun. 7, 2022.
Claims priority of provisional application 62/977,659, filed on Feb. 17, 2020.
Claims priority of provisional application 62/941,160, filed on Nov. 27, 2019.
Claims priority of provisional application 62/902,019, filed on Sep. 18, 2019.
Claims priority of provisional application 62/899,257, filed on Sep. 12, 2019.
Prior Publication US 2024/0041845 A1, Feb. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/438 (2006.01); A61K 9/00 (2006.01); A61K 31/546 (2006.01); A61K 38/12 (2006.01); A61P 31/04 (2006.01)
CPC A61K 31/438 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 9/0053 (2013.01); A61K 9/0073 (2013.01); A61K 31/546 (2013.01); A61K 38/12 (2013.01); A61P 31/04 (2018.01)] 24 Claims
OG exemplary drawing
 
1. A method of treating A. baumannii infection, the method comprising: administering to a patient a composition comprising an aqueous solution of rifabutin.